Table 1 General characteristics of patients during first-line treatment.
From: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
N=218 (%) | |
|---|---|
Age (years) | 60 (33.8-76.6) |
Sex | |
Male | 134 (61.5) |
Female | 84 (38.5) |
Disease state at the time of diagnosis | |
Non-metastatic | 47 (21.6) |
Metastatic | 171 (78.4) |
ECOG at the time of diagnosis | |
0-1 | 187 (85.7) |
2 | 31 (14.3) |
PFS after first-line treatment (months) | 6.8 (6.1-7.4) |
OS after first-line treatment (months) | 17.9 (16.2-19.6) |
